Form 8-K HERON THERAPEUTICS, INC. For: Aug 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
August 10, 2016 12:50 PM EDTBelow is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:
... MoreFDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - Analyst
August 10, 2016 11:14 AM EDTLeerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for treatment of chemo induced nausea and vomiting.
Analyst Jason Gerberry commented today: We are still reviewing the package insert, but Sustol... More
